MX2019001804A - Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. - Google Patents
Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.Info
- Publication number
- MX2019001804A MX2019001804A MX2019001804A MX2019001804A MX2019001804A MX 2019001804 A MX2019001804 A MX 2019001804A MX 2019001804 A MX2019001804 A MX 2019001804A MX 2019001804 A MX2019001804 A MX 2019001804A MX 2019001804 A MX2019001804 A MX 2019001804A
- Authority
- MX
- Mexico
- Prior art keywords
- neurodegenerative disorders
- modified peptides
- treating neurodegenerative
- treating
- peptides
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 108091005601 modified peptides Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1613999.0A GB201613999D0 (en) | 2016-08-16 | 2016-08-16 | Neurodegenerative disorders |
| GBGB1701455.6A GB201701455D0 (en) | 2016-08-16 | 2017-01-30 | Neurodegenerative disorders |
| PCT/GB2017/052407 WO2018033724A1 (en) | 2016-08-16 | 2017-08-16 | Modified peptides for use in treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001804A true MX2019001804A (es) | 2019-07-01 |
Family
ID=56985964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001804A MX2019001804A (es) | 2016-08-16 | 2017-08-16 | Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11939398B2 (ja) |
| EP (1) | EP3500252B1 (ja) |
| JP (1) | JP7125143B2 (ja) |
| KR (1) | KR102457935B1 (ja) |
| CN (1) | CN109640972B (ja) |
| AU (1) | AU2017313372B2 (ja) |
| BR (1) | BR112019003189A2 (ja) |
| CA (1) | CA3033497A1 (ja) |
| ES (1) | ES2930320T3 (ja) |
| GB (2) | GB201613999D0 (ja) |
| MX (1) | MX2019001804A (ja) |
| RU (1) | RU2756052C2 (ja) |
| WO (1) | WO2018033724A1 (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201613999D0 (en) | 2016-08-16 | 2016-09-28 | Neuro-Bio Ltd | Neurodegenerative disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013633A (en) * | 1997-08-07 | 2000-01-11 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| IL146009A0 (en) | 1999-05-05 | 2002-07-25 | Neurochem Inc | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
| MXPA02001349A (es) | 1999-08-09 | 2002-07-22 | Tripep Ab | Inhibidores de la polimerizacion de proteinas y metodos de uso. |
| EP1351976A2 (en) * | 2000-08-24 | 2003-10-15 | Neuronz Limited | Gpe analogs |
| CN1535264A (zh) * | 2001-05-15 | 2004-10-06 | ������ҩ��ʽ���� | 精氨酸衍生物 |
| JP2004155695A (ja) * | 2002-11-06 | 2004-06-03 | Taisho Pharmaceut Co Ltd | Ｍｃ４受容体に対するリガンド |
| US20050159362A1 (en) * | 2003-04-22 | 2005-07-21 | Sircar Jagadish C. | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
| KR101215821B1 (ko) | 2003-06-30 | 2012-12-28 | 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. | 아밀로이드 관련 질환을 진단 및 처치하기 위한 펩타이드, 그것에 대한 항체, 및 그 사용방법 |
| JP2006347951A (ja) * | 2005-06-16 | 2006-12-28 | Yoshihiro Futamura | 神経細胞活性化作用を有するトリペプチド、それからなる食品製剤、化粧品及び抗認知症剤 |
| GB2432586B (en) * | 2005-11-25 | 2010-01-13 | Univ Open | Treatment of neurodegenerative disorders |
| US20140349920A1 (en) | 2012-01-03 | 2014-11-27 | Ruey J. Yu | N-acylpeptide derivatives and their uses |
| GB2516045A (en) * | 2013-07-09 | 2015-01-14 | Neuro Bio Ltd | Neurodegenerative disorders |
| GB201613999D0 (en) | 2016-08-16 | 2016-09-28 | Neuro-Bio Ltd | Neurodegenerative disorders |
-
2016
- 2016-08-16 GB GBGB1613999.0A patent/GB201613999D0/en not_active Ceased
-
2017
- 2017-01-30 GB GBGB1701455.6A patent/GB201701455D0/en not_active Ceased
- 2017-08-16 AU AU2017313372A patent/AU2017313372B2/en active Active
- 2017-08-16 US US16/325,716 patent/US11939398B2/en active Active
- 2017-08-16 CN CN201780049754.8A patent/CN109640972B/zh active Active
- 2017-08-16 ES ES17757821T patent/ES2930320T3/es active Active
- 2017-08-16 RU RU2019103805A patent/RU2756052C2/ru active
- 2017-08-16 MX MX2019001804A patent/MX2019001804A/es unknown
- 2017-08-16 JP JP2019509482A patent/JP7125143B2/ja active Active
- 2017-08-16 BR BR112019003189A patent/BR112019003189A2/pt active Search and Examination
- 2017-08-16 EP EP17757821.8A patent/EP3500252B1/en active Active
- 2017-08-16 KR KR1020197007539A patent/KR102457935B1/ko active IP Right Grant
- 2017-08-16 WO PCT/GB2017/052407 patent/WO2018033724A1/en unknown
- 2017-08-16 CA CA3033497A patent/CA3033497A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017313372A1 (en) | 2019-03-07 |
| EP3500252B1 (en) | 2022-11-02 |
| WO2018033724A1 (en) | 2018-02-22 |
| JP7125143B2 (ja) | 2022-08-24 |
| RU2019103805A3 (ja) | 2020-10-30 |
| US11939398B2 (en) | 2024-03-26 |
| GB201613999D0 (en) | 2016-09-28 |
| EP3500252A1 (en) | 2019-06-26 |
| CN109640972A (zh) | 2019-04-16 |
| RU2019103805A (ru) | 2020-09-21 |
| RU2756052C2 (ru) | 2021-09-24 |
| KR102457935B1 (ko) | 2022-10-21 |
| JP2019532028A (ja) | 2019-11-07 |
| ES2930320T3 (es) | 2022-12-09 |
| CA3033497A1 (en) | 2018-02-22 |
| US20210094983A1 (en) | 2021-04-01 |
| AU2017313372B2 (en) | 2022-12-22 |
| CN109640972B (zh) | 2023-05-26 |
| KR20190039271A (ko) | 2019-04-10 |
| GB201701455D0 (en) | 2017-03-15 |
| BR112019003189A2 (pt) | 2019-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901924B (en) | Anti¿lag¿3 antibodies and compositions | |
| SA519400950B1 (ar) | Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة | |
| PH12018502664A1 (en) | Variant adeno-associated viruses and methods of using | |
| PH12018500233A1 (en) | Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| PH12018500016A1 (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| MX2019007480A (es) | Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau. | |
| PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
| MX2019000047A (es) | Inhibidores peptídicos de la acumulación de alfa-sinucleína basados en estructuras. | |
| MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
| MY184878A (en) | Compositions and methods for treating neurodegenerative diseases | |
| NI202000005A (es) | Agentes, usos y métodos para el tratamiento | |
| MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
| MX2017012397A (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| EP3702470A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| MX2020006140A (es) | Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas. | |
| MX2017006692A (es) | Trastornos neurodegenerativos. | |
| CR20220228A (es) | Anticuerpos trem2 y usos de estos | |
| MX2019001804A (es) | Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. | |
| MX2017002277A (es) | Anticuerpos que potencian el factor h y sus usos. | |
| MX2019009293A (es) | Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos. | |
| PH12021550213A1 (en) | Methods for treating neurodegenerative disorders | |
| MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. |